Bayer and CRISPR Therapeutics JV starts operations in Massachusetts, US
The JV, which was initially announced in December 2015, will focus on the discovery, development and commercialization of new therapeutics to treat blood disorders, blindness, and congenital heart
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.